Literature DB >> 11136374

Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay.

K Ghosh1, S Shetty, D Mohanty.   

Abstract

During the course of investigations we encountered 11 patients with haemophilia A who had severe factor VIII deficiency as measured by one-stage assay but had surprisingly mild clinical presentation. Four of these patients had either a brother, nephew or maternal uncle with severe clinical manifestations. Two patients had low protein S levels, and one was heterozygous for the factor V Leiden mutation. One patient had a combined deficiency of protein C and antithrombin III. Four patients had a two-stage factor VIII assay value that was much higher than the one-stage assay value. Five patients were heterozygous for the MTHFR gene C677T polymorphism, of whom two patients were also deficient for protein S and one had two-stage factor assay values higher than the one-stage assay values. The patient who was both factor VIII deficient and heterozygous for factor V Leiden had mild clinical presentation as compared to his maternal uncle who was only factor-VIII deficient. The maternal cousin of the same patient was heterozygous for factor V Leiden and had suffered two thrombotic episodes. Thus, the present study advocates that the physiological inhibitors of blood coagulation also play an important role in cases of haemophilia A in the final outcome of haemostasis in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136374     DOI: 10.1046/j.1365-2516.2001.00455.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

Review 2.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

3.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

4.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

Review 5.  Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.

Authors:  Kim Fechtel; Marika L Osterbur; Hildegard Kehrer-Sawatzki; Peter D Stenson; David N Cooper
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

6.  Coagulation disorders seen through the window of molecular biology.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2007-09

Review 7.  Clinical and laboratory approaches to hemophilia a.

Authors:  Hassan Mansouritorghabeh
Journal:  Iran J Med Sci       Date:  2015-05

8.  Genetic biomarkers related to hemarthrosis, inflammation, and cartilage structure in pediatric patients with hemophilic arthropathy.

Authors:  José de Jesús López-Jiménez; Ricardo Ortega-Cervantes; Hilda Luna-Záizar; Ana-Lilia Fletes-Rayas; Claudia-Patricia Beltrán-Miranda; Rogelio Troyo-Sanromán; Janet Soto-Padilla; Alberto Tlacuilo-Parra; Ana-Rebeca Jaloma-Cruz
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

9.  Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.

Authors:  Romy M W de Laat-Kremers; Marisa Ninivaggi; Iris van Moort; Moniek de Maat; Bas de Laat
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.